Oragenics Inc
OGEN
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.73M
Close$
$0.08
86.7% downside
Current Fair Value
86.7% downsideOvervalued by 86.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.73 Million |
|---|---|
| Enterprise Value | $-3,317,600.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-4.56 |
| Beta | 1.26 |
| Outstanding Shares | 4,300,980 |
Return
| Return on Equity | -158.96% |
|---|---|
| Return on Assets | -131.20% |
| Return on Invested Capital | -128.18% |
Valuation & Multiples
| P/E Ratio | -0.27 |
|---|---|
| PEG | 37.32 |
| Price to Sales | - |
| Price to Book Ratio | 0.61 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.35 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.02 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 18, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 11, 2026
EPS Estimate
$-72.00
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 4.43%▼ 0.63% |
|---|---|
| Total Invested | $106,344▼ 37.17% |
| Investors Holding | 19▲ 4.00% |
ESG Score
No data
About Oragenics Inc
7 employeesOragenics, Inc. is focused on the creation of the Terra CoV-2 vaccine candidate to combat the novel coronavirus pandemic and the further development of effective treatments for novel antibiotics against infectious disease. The Company is...